Successful First inclusion of Kalumi study

On March 09, 2021, the WANECAM 2 research team in Bougoula Hameau, Sikasso proceeded to the inclusion of the first patient in the KALUMI protocol.

Upon the patient’s arrival, a consent and a pre-selection assent was carried out. After the signature of the informed consent document, a thick blood was carried out to determine the parasitemia of inclusion.

After verifying compliance with all the inclusion criteria, the patient was randomized to the treatment regimen through the «Cenduit Solution» platform.

Thus the drug was administered successfully under the supervision of the clinical investigators  after dispensing by the study pharmacist.

Monitoring is underway for the safety and effectiveness of the drug KAF156 + LUM-SDF.